Chelsie Derman

Schizophrenia experts discuss the stigma and misconceptions surrounding schizophrenia as well as current treatment options.

A study found children and young adults with cerebral palsy have more anxiety and less depression than those with a chronic condition or who are typically developed.

A study shows it is safer for nursing home residents on CYP2D6 opioids to take CYP2D6-neutral antidepressants than CYP2D6-inhibiting antidepressants.

Johnson & Johnson submits a supplemental New Drug Application to the FDA for the approval of esketamine as a monotherapy for adults with treatment-resistant depression.

The phase 2 findings set up the foundation to design a phase 3 trial evaluating KP1077 for idiopathic hypersomnia.

A new study found individuals with depression and anxiety have a high prevalence of medical debt.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.

A new study showed the efficiency and speed of a new AI model for a heart scan.

A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.

A new study confirms GLP-1RAs do not increase the risk for suicidal thoughts or behaviors, aligning with the FDA findings.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

A study showed participants with symptoms of anxiety and depression had significantly fewer controlled cardiovascular disease risk factors.

Emerging treatments for CSA include hypochlorite phrenic nerve stimulation and pharmacological intervention, Badr told HCPLive.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.

Cook explains to HCPLive how elite athletes can optimize sleep for peak performance.

Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.

Gozal told HCPLive about the issue of the classic approach when diagnosing children with OSA.

HCPLive spoke with Joshua M. Cohen, MD, MPH, to discuss a post-hoc analysis of a phase 3 study that showed buprenorphine may be effective at reducing fentanyl use.

This Month in Review spotlights interviews conducted at SLEEP 2024 and a recent FDA approval.

Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.

This month in review captures the top FDA updates, including the first FDA Advisory Committee meeting to discuss the NDA for a psychedelic-assisted therapy.

FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.

Machine learning outperformed clinical diagnostic criteria and the recommended screening criteria in the United Kingdom in identifying familial hypercholesterolemia.

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

FDA approves pitolisant for excessive daytime sleepiness and cataplexy in pediatric patients aged ≥ 6 years with narcolepsy.

Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.

The study APEX-002-B01-02 will evaluate how APEX-52, a microdose psilocybin, can impact safe driving.

A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.

Phase 3 data presented at EULAR found the biosimilar CT-P47 is similar to its reference product, tocilizumab, regarding efficacy, safety, and immunogenicity.